Ownership and insider activity for Bluejay Diagnostics, Inc. (BJDX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force.
Price
| Price | $0.81 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $96011 | $912361 | $19.0M | $10.1M | $2.2M | $4.3M | $5.2M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $645 | 0 | 0 | 0 | $41269 | $14564 | 0 |
| Inventory | $123508 | $84762 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $300341 | $1.1M | $20.7M | $11.8M | $3.2M | $4.9M | $5.5M |
| Property, Plant & Equipment | $611558 | $459138 | $332747 | $1.7M | $1.6M | $1.7M | $1.6M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $4619 | $4619 | $4619 | $4457 | 0 | 0 | 0 |
| Total Assets | $916518 | $1.5M | $21.0M | $13.5M | $4.9M | $6.7M | $7.1M |
| Accounts Payable | $29125 | $374928 | $295778 | $635818 | $491474 | $145122 | $214255 |
| Short-term Debt | $265000 | $1.1M | 0 | 0 | 0 | $113260 | 0 |
| Total Current Liabilities | $576538 | $1.8M | $637162 | $1.6M | $1.8M | $810368 | $1.1M |
| Long-term Debt | $804288 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $3.8M | $5.7M | $637162 | $2.0M | $2.0M | $927924 | $1.1M |
| Retained Earnings | -$2.9M | -$4.2M | -$7.7M | -$17.0M | -$27.0M | -$34.7M | -$41.5M |
| Total Equity | -$2.9M | -$4.2M | $20.4M | $11.5M | $2.9M | $5.7M | $6.0M |
| Total Debt | $1.1M | $1.1M | 0 | $492621 | $352977 | $222249 | $120211 |
| Net Debt | $973277 | $143550 | -$19.0M | -$9.6M | -$1.9M | -$4.1M | -$5.0M |
| Working Capital | -$276197 | -$787196 | $20.0M | $10.1M | $1.4M | $4.1M | $4.3M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 4.64 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -10.03 |
Profitability
| Return on Equity | -125.01% |
| Return on Invested Capital | -77.55% |
| Return on Assets | -63.04% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: BCTXZ · ELAB · MLEC · MSPR · NKGN · TIVC · UPC
Explore sector: Healthcare · Medical - Devices
More sections of BJDX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks